Bausch + Lomb Acquires Diagnostic Company Trukera Medical

Bausch + Lomb announced it has acquired US-based privately held ophthalmic medical diagnostic company Trukera Medical. Financial terms of the deal were not disclosed. An affiliate of B+L acquired Trukera from its private equity owner, AccelMed Partners, and other shareholders. 

The tuck-in acquisition will help expand Bausch + Lomb’s surgical presence in the United States and contribute to its dry eye portfolio. Trukera Medical commercializes ScoutPro, a point-of-care portable device for precisely measuring osmolarity. Hyperosmolarity, a condition not detectable by slit lamp examination, is a leading indicator and central etiology of asymptomatic dry eye disease (DED) and ocular surface disease (OSD), which can negatively affect corneal, cataract and refractive surgery outcomes if not treated effectively prior to the procedure.

“As a global leader in dry eye disease management, as well as cataract and refractive medical devices and implants, we’re uniquely positioned to optimize pre-surgical preparation to help ensure positive post-surgical outcomes,” Luc Bonnefoy, president, Surgical, Bausch + Lomb, said in a company news release. “ScoutPro has already become a valuable preoperative diagnostic tool for many U.S. surgeons, and with our scale we believe it can have an even greater impact.”

“Premium outcomes today are increasingly measured by an ability to deliver both the refractive target and a high quality of vision for each patient. Since hyperosmolarity is known to have a significant negative impact on quality of vision and patient satisfaction after cataract surgery, having an easy-to-use diagnostic tool can help surgeons meet their patients’ increasingly high expectations,” said Adam Szaronos, CEO and president of Trukera Medical. “By joining a global leader like Bausch + Lomb, we are excited to get this valuable tool in the hands of more surgeons to benefit more patients.”

Founded in 2009, Trukera (formerly TearLab), introduced tear osmolarity testing to eye care with the TearLab Osmolarity System, which has been used to perform over 24 million tests worldwide. In 2022, the company changed its name to Trukera Medical as it expanded into corneal health.